NEW YORK, Feb. 23 (GenomeWeb News) - PONT (Parallel Optimization of New Technologies for Post-Genomics Drug Discovery), a research project piloted by British, Austrian, and German biotech companies and academic researchers, will be using €2.5 million in European Union grant money to find genome targets in liver cancer, project leaders said yesterday.
PONT representatives said they will rely on a strategy of parallel pre-clinical drug development, rather than sequential, to lessen the time it takes to bring a drug to trial. Other areas they are concentrating on are human tissue resources, RNA technology, and structural proteomics.
PONT received the funding in May 2004 from the EU's 6th Framework Program. The consortium is led by Graz, Austria-based Oridis Biomed; the Medical University of Graz' Institute of Pathology; Berlin-based PSF Biotech; the Free University of Berlin's Institute of Crystallography; Munich, Germany-based Nascacell IP; and the Bude, UK-based Tripos Receptor Research.